诺和诺德面临“验证”时刻:美国山寨药禁令后如何重振Wegovy增长势头

华尔街见闻
28 Jul

诺和诺德正面临投资者信心的"证明时刻"。尽管美国禁止Wegovy仿制药版本已开始提振这款减肥药的使用量,但市场对该公司能否在未来几个月展现更强劲增长仍持谨慎态度。 据IQVIA数据显示,自5月22日美国食品药品监督管理局禁止所谓复配版本的Wegovy生效以来,新的Wegovy处方量增长约33%,在7月18日当周达到181200份。这一增长缩小了与礼来公司Zepbound的差距——5月23日当周,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10